TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02178839

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β- glucan
Description: 8.5 g/d of Oat Supplement Containing 3g β- glucan

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 8.5 g/d Maltodextrin
Study: NCT02487342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk
Description: small serving (217 mL) of british semi-skimmed milk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: orange fruit-juice
Description: small serving (217 mL) of orange juice
Study: NCT01311635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981, current small-particle tablet
Description: 3x100 mg per oral, single dose in fasted state
Study: NCT03561402

Intervention type: DRUG
Intervention: Teriflunomide
Description: Each patient will receive 1 tablet (14 mg) on a daily basis.
Study: NCT01311635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981, new small-particle tablet
Description: 3x100 mg per oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981, new small-particle tablet
Description: 3x100 mg per oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981, new large-particle table
Description: 3x100 mg per oral, single dose in fasted state
Study: NCT03441672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning of Screening
Description: Interactive technology game providing education about prenatal screening and what the results may mean.
Study: NCT00732004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone Hydrogel Contact Lenses
Study: NCT02835170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous immunoglobulin
Description: Autologous immunoglobulin (total IgG) aseptically purified from the autologous plasma will be administered to the patients by intramuscular injection, once a week for 7 weeks (total 8 injections).
Study: NCT00732004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1x PMBH preserved MPS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1x Polyquad/Aldox MPS
Study: NCT04011371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate closure
Description: Cyanoacrylate glue embolization targeting venous insufficiency
Study: NCT00746200

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (electro)acupuncture
Description: Frequency of electrostimulation: 15Hz; Duration of electrostimulation: 20min;
Study: NCT02835170

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be administered to the patients by intramuscular injection, once a week for 7weeks (total 8 injections).~(In addition, autologous immunoglobulin is colorless and odorless, injection volume is same between autologous immunoglobulin and saline)
Study: NCT03870841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC945
Description: PC945, nebulized
Study: NCT05346107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by Nab-paclitaxel (Nab-P) ,continuously combined with dual HER2 blockage
Description: The patients were treated with PldCHP (pegylated liposomal doxorubicin 35mg/m2, cyclophosphamide 600mg/m2, trastuzumab 8 mg/kg loading, then 6 mg/kg, pertuzumab 840 mg loading, then 420 mg, iv, q3w) for 4 cycles followed by Nab-PHP (Nab-Paclitaxel 260mg/m2, trastuzumab 6 mg/kg, pertuzumab 420 mg, iv, q3w) for 4 cycles, with strict monitoring of cardiotoxicity.
Study: NCT04801290

Intervention type: PROCEDURE
Intervention: TIPS insertion
Description: Patients are included in the registry if they receive a transjugular intrahepatic portosystemic shunt at Hannover Medical School and provide written informed consent.
Study: NCT03967821

Intervention type: OTHER
Intervention: Questionnaire
Description: Each patient complete FQoR-15 questionnaire 3 times (before surgery, on Day 1, on Day 2)
Study: NCT01790490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.41 mg/kg
Description: 52 minute iv infusion of ketamine 0.41 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.71 mg/kg
Description: 52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Description: 52 minute infusion of lorazepam 2 mg. This serves as an active control.
Study: NCT00863551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trospium Chloride
Description: Extended release, 60 mg, oral daily
Study: NCT01780792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance Dance Revolution video game play
Description: Individuals play dance dance revolution 3 times a week for 8 weeks
Study: NCT00737139

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri-articular injection of marcaine/epinephrine
Description: 60ml of 0.5% Bupivacaine and Epinephrine 1:200,000 Inj

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri-articular injection of marcaine alone
Description: 60ml of 0.5% Bupivacaine
Study: NCT01879410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI
Description: The drug is administered via NDPI as one inhalation once daily in the morning. NDPI has two strips, each containing 30 blisters of medication. The first strip has UMEC blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 62.5 mcg per blister and the second strip has VI blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 25 mcg per blister.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS
Description: The drug is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains a single strip with 60 blisters of medication. The strip has 250 mcg of fluticasone propionate and 50 mcg of salmeterol per blister in the form of dry white powder.
Study: NCT00746200

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: Superficial acupuncture needle stimulation at non-acupoints with TENS applied for seconds
Study: NCT00296647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion
Description: dosage according to prescription directions: 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patch + lozenge
Description: dosage of each according to package insert directions (12 weeks patch, 16 weeks lozenge)
Study: NCT06047184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-209 capsules
Description: BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
Study: NCT01879410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo DISKUS
Description: Placebo is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains 1 strip with 60 blisters of placebo in the form of dry white powder.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo NDPI
Description: Placebo is administered via NDPI as one inhalation once daily in the morning. The inhaler contains 2 strips with 30 blisters of placebo per strip in the form of dry white powder.
Study: NCT06047184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-209 capsules
Description: BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-209 capsules
Description: BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-209 capsules
Description: BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-209 capsules
Description: BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-209 capsules
Description: BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-209 capsules
Description: BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
Study: NCT02774993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Study: NCT00296647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion + lozenge
Description: dosage of each according to prescription or package insert (12 weeks bupropion, 16 weeks lozenge)
Study: NCT06047184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-209 capsules
Description: BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-209 capsules
Description: BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole tablets
Description: Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole tablets
Description: Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle
Study: NCT02774993

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00918944

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The asthma disease management toolkit available to all practices in the EHR will consist of four elements:~* A data entry tool for capturing asthma control data~* Standardized documentation templates to facilitate severity classification~* Order sets to facilitate ordering controller medications~* An asthma care plan that can be supplied to families

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention
Description: Three alerts and two reminders will be programmed:~* Alert providers to enter asthma severity classification if none is on file~* Alert providers to prescribe controller medications for persistent asthma if none on file~* Alert providers to complete an asthma care plan if none on file~* Remind providers to review the asthma care plan if it is already on file by providing a link to the form~* Remind providers that educational content is available on-line by providing a web link
Study: NCT01855256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: Oxybutynin is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
Study: NCT01860937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis or collection of PBMCs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis or collection of PBMCs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide based chemotherapy regimens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide based chemotherapy regimens

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: modified T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: modified T cells
Study: NCT04514263

Intervention type: OTHER
Intervention: OHIP-14 Administration
Description: All patients fulfilled the OHIP-14 questionnaire three times: six hours, seven days and twenty-one days after the biopsy

Intervention type: OTHER
Intervention: VNS Administration
Description: All patients fulfilled the VNS scale three times: six hours, seven days and twenty-one days after the biopsy
Study: NCT06047184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle
Study: NCT03965143

Intervention type: DEVICE
Intervention: 3D talar augmentation
Description: Patients with an avascular necrosis of the body if the talar bone will undergo a 3D custom talar augmentation with or without concomitant ankle arthroplasty
Study: NCT02098876

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity Zotarolimus eluting stent
Description: PCI with Resolute stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience Xpedition everolimus eluting stent
Description: PCI with Xience stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography (OCT)
Description: Optical coherence tomography (OCT) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. OCT will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area and stent area will be performed for each OCT cross-section from baseline and follow up examinations.
Study: NCT02232256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CALPXT96
Description: Arm 1: intervention begins with CALPXT96 Arm 2: intervention begins with placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CALPXT96
Description: Arm 1: intervention begins with CALPXT96 Arm 2: intervention begins with placebo
Study: NCT03463772

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard IVF
Description: Ovarian stimulation will be performed by a standard protocol using gonadotrophin-releasing hormone antagonist (GnRH-ant) in association with recombinant FSH (rFSH) and human chorionic gonadotrophin (hCG).Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be inseminated using ICSI or conventional IVF according to the seman analysis. All embryos will be cultured to blastocyst stage and be vitrified.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: In vitro maturation
Description: Controlled ovarian stimulation protocol will not performed in this group patients. Transvaginal ultrasound scanning was examined on natural cycle to monitor the follicle size in group B participants. Oocyte retrieval was scheduled once the endometrium had reached at least 6 mm in thickness and there was no follicle larger than 10 mm. After oocyte retrieval, the COCs will be cultured for 28-32h in special IVM media in order to get the matured oocytes. All the metaphase II (MII) oocytes were inseminated by means of intracytoplasmic sperm injection (ICSI). All embryos will be cultured to blastocyst stage and be vitrified.
Study: NCT03709992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trospium Chloride
Description: 30 mg of Trospium chloride tablet twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 0.4 mg of Tamsulosin tablet once daily
Study: NCT01592994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RHANI WIves
Description: The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT)10 and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
Study: NCT02098876

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography (OCT)
Description: Optical coherence tomography (OCT) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. OCT will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area and stent area will be performed for each OCT cross-section from baseline and follow up examinations.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravascular Ultrasound (IVUS)
Description: Intravascular ultrasound (IVUS) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. IVUS will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area, stent area, vessel area (external elastic membrane) and the media-adventitia interface will be performed for each IVUS cross-section from baseline and follow up examinations.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravascular Ultrasound (IVUS)
Description: Intravascular ultrasound (IVUS) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. IVUS will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area, stent area, vessel area (external elastic membrane) and the media-adventitia interface will be performed for each IVUS cross-section from baseline and follow up examinations.
Study: NCT00124345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR730
Description: humidity measurement inside the helmet by a capacitative hygrometer and evaluation of patients' comfort
Study: NCT01254942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B4 Clinic
Description: Fracture Follow-Up Clinic plus Exercise Program
Study: NCT00257673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEM 1003
Description: 30 mg twice a day
Study: NCT01254942

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study: NCT02622906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pasireotide
Description: 60 mg per month of the Pasireotide during 6 months
Study: NCT02557425

Intervention type: OTHER
Intervention: No intervention in PROTECT

Intervention type: OTHER
Intervention: No intervention in PROTECT
Study: NCT00257673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEM 1003
Description: 90 mg MEM 1003 twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MEM 1003
Description: Placebo twice a day
Study: NCT00986245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole Prolonged release
Description: Change Ropinirole immediate release or Pramipexole immediate release to Ropinirole prolonged release (PR) once-daily or twice-daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole Prolonged release
Description: Change Ropinirole immediate release or Pramipexole immediate release to Ropinirole prolonged release (PR) once-daily or twice-daily
Study: NCT02167620

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin will be dispensed on a biweekly basis, and pill counts conducted at each visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
Study: NCT00550563

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Oral
Study: NCT02557425

Intervention type: OTHER
Intervention: No intervention in PROTECT

Intervention type: OTHER
Intervention: No intervention in PROTECT

Intervention type: OTHER
Intervention: No intervention in PROTECT
Study: NCT01880307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Study: NCT00550563

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: companion study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: companion study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: companion study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: companion study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: companion study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: companion study
Study: NCT02622906

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicule injection per month during 6 months
Study: NCT00550563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: companion study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: companion study
Study: NCT01880307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Study: NCT00550563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Additional therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immunoscintigraphy
Description: additional testing